Deutsche Bank analyst Andrew Peters lowered his price target for Prothena $16 from $78 to reflect NEOD001 being taken out of his model. The analyst, however, still thinks the company's total value is underappreciated following yesterday's selloff. Prothena's "strong" cash position and "interesting" pipeline could host several upside drivers over the next 12-24 months, Peters tells investors in a research note. He keeps a Buy rating on the shares. The analyst believes the value of the pipeline, strength of the balance sheet and quality of management are underappreciated at current share levels.